Thomson launches Prous Predictive Pharmacology Module

The scientific business of Thomson Reuters has launched the Prous Science Integrity Predictive Pharmacology Module. Available through the Prous Science Integrity platform, the new discovery tool provides expert insight into the probable mechanisms of action of thousands of bioactive compounds.

The Predictive Pharmacology Module is based on technology developed at the Prous Institute for Biomedical Research, a research organization focused on experimental and data-mining methods.

The module details up to three potential mechanisms of action for nearly 100,000 lead compounds with chemical structures in Prous Science Integrity and includes unique visualization tools. According to the firm, the module will help to accelerate experimental research and identify new indications for existing drugs before they reach trial stage by allowing scientists to validate new drug discovery hypotheses and become aware of mechanisms of action that may cause adverse effects. In addition, it can be used by business development analysts for pharmaceutical companies to develop drug repurposing strategies.